The Department of Defense Office of Inspector General (DoD OIG) announced today that it released the “Evaluation of Incurred Cost Audits Performed by Non-Federal Auditors for Compliance with Government Auditing Standards.” “Government Auditing Standards are crucial because they ensure the integrity, accountability, and transparency of Government operations,” said IG Storch.

The Department of Defense Office of Inspector General (DoD OIG) announced today that it released the “Audit of the DoD Government Travel Charge Card Program: The Visa IntelliLink Compliance Management System.” The DoD OIG found that the DoD’s Government Travel Charge Card (GTCC) program officials did not effectively use policies, procedures, or the Visa IntelliLink Compliance Management data mining system (VICM system) to identify misuse, abuse, or potential fraud. The Defense Travel Management Office’s (DTMO) implementation and management of the VICM system limited the system’s effectiveness in identifying and assisting reviewers in investigating high-risk GTCC transactions where misuse, abuse, and fraud were more likely.

The Department of Defense Office of Inspector General (DoD OIG) announced today that it released the “Audit of the Army’s Management of Undefinitized Contract Actions Awarded to Provide Ukraine Assistance.”

The objective of the audit was to determine whether the Military Services in Japan provided oversight over and processed hazardous waste disposals in accordance with DoD requirements.

This quarterly report describes the activities of the U.S. Government in support of OIR as well as the work of the Department of Defense (DoD), the Department of State (State), and the U.S. Agency for International Development (USAID) to further the U.S. Government’s policy goals in Iraq and Syria during the period of January 1 through March 31, 2025. This report also discusses the planned, ongoing, and completed oversight work conducted by the Lead IG agencies—the DoD, State, and USAID OIGs—and our partner oversight agencies.

The objective of this audit was to determine whether the DoD complied with FY 2022 National Defense Authorization Act (NDAA) requirements to develop the DoD Zero Trust (ZT) strategy, principles, architecture, and implementation plans.

The Justice Department today announced that it has declined the prosecution of Universities Space Research Association (USRA) after it self-disclosed to the Department’s National Security Division (NSD) criminal violations of U.S. export control laws committed by its former employee, Jonathan Soong. Soong pleaded guilty to willfully violating the Export Administration Regulations (EAR) by exporting U.S. Army-developed aviation software to a university in the People’s Republic of China (PRC) that had been placed on the Commerce Department’s Entity List and was sentenced to 20 months in prison.

Gilead Admits to Paying Hundreds of Thousands of Dollars to High Prescribers of Gilead’s HIV Drugs to Serve as Speakers at Programs and to Holding Programs at Luxury Restaurants Jay Clayton, the United States Attorney for the Southern District of New York; Naomi Gruchacz, the Special Agent in Charge of the New York Regional Office of the U.S. Department of Health and Human Services, Office of Inspector General (“HHS-OIG”); Christopher M. Silvestro, the Acting Special Agent in Charge of the Northeast Field Office of the Defense Criminal Investigative Service (“DCIS”), the law enforcement arm of the Department of Defense’s Office of Inspector General (“DOD-OIG”); and Christopher G. Raia, the Assistant Director in Charge of the New York Field Office of the Federal Bureau of Investigation (“FBI”), announced today that the U.S. has settled a civil fraud lawsuit against GILEAD SCIENCES, INC (“GILEAD”), a large pharmaceutical manufacturer, that, among other things, develops, manufactures, and sells drugs for the treatment of infectious diseases, including HIV/AIDS. The settlement resolves claims that GILEAD offered and paid kickbacks in the form of honoraria payments, meals, and travel expenses to healthcare practitioners who spoke at or attended Gilead speaker events to induce them to prescribe Stribild®, Genvoya®, Complera®, Odefsey®, Descovy®, and Biktarvy® (the “Gilead HIV Drugs”) in violation of the Anti-Kickback Statute (“AKS”) and thereby caused false claims for the Gilead HIV Drugs to be submitted to and paid by federal healthcare programs in violation of the False Claims Act.

Two former laboratory sales executives were sentenced to federal prison for conspiring to violate the Anti-Kickback Statute, announced Acting U.S. Attorney Abe McGlothin, Jr.